Roche announced on March 16, 2026, an expansion of its Nvidia partnership, adding 2,176 Blackwell GPUs to create the pharmaceutical industry's largest hybrid-cloud AI factory with over 3,500 GPUs total.
The AI factory spans U.S. and Europe sites, accelerating therapeutics, diagnostics, drug discovery, manufacturing, digital pathology, and digital health.
It builds on a 2023 Genentech-Nvidia collaboration and supports Roche's 'Lab-in-the-Loop' strategy using Nvidia BioNeMo.
This eclipses Eli Lilly's recent Nvidia supercomputer, positioning Roche as leader in AI-driven pharma innovation.
Quotes from Roche executives highlight embedding AI across the value chain to speed up medicine and diagnostic delivery.